Bernadette Laxa
YOU?
Author Swipe
View article: Data from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Data from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
Purpose:Dedifferentiated liposarcoma (DDLS), one of the most common and aggressive sarcomas, infrequently responds to chemotherapy. DDLS survival and growth depend on underexpression of C/EBPα, a tumor suppressor and transcriptional regula…
View article: Figure S2 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S2 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
SN-38 inhibits cell viability and increases expression of C/EBP� in the nucleus in DDLS cells.
View article: Supplementary Table 1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Supplementary Table 1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
List of compounds used in the screen
View article: Figure S1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
Copy number, methylation status, and expression of CEBPA in liposarcoma cell lines.
View article: Data from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Data from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
Purpose:Dedifferentiated liposarcoma (DDLS), one of the most common and aggressive sarcomas, infrequently responds to chemotherapy. DDLS survival and growth depend on underexpression of C/EBPα, a tumor suppressor and transcriptional regula…
View article: Supplementary Table 1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Supplementary Table 1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
List of compounds used in the screen
View article: Figure S4 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S4 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
Irinotecan does not cause gross toxicity and induces C/EBPα expression in DDLS tumors in vivo, while doxorubicin leads to weight loss.
View article: Figure S3 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S3 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
SN-38/irinotecan suppresses HIF1� expression in vitro and in vivo.
View article: Figure S3 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S3 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
SN-38/irinotecan suppresses HIF1� expression in vitro and in vivo.
View article: Figure S1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
Copy number, methylation status, and expression of CEBPA in liposarcoma cell lines.
View article: Figure S4 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S4 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
Irinotecan does not cause gross toxicity and induces C/EBPα expression in DDLS tumors in vivo, while doxorubicin leads to weight loss.
View article: Figure S2 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Figure S2 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
SN-38 inhibits cell viability and increases expression of C/EBP� in the nucleus in DDLS cells.
View article: Supplementary Figure 1 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Figure 1 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Figure 1 from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1B from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1B from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1B from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1A from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1A from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1A from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1D from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1D from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1D from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Figure 2 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Figure 2 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Figure 2 from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Figure 2 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Figure 2 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Figure 2 from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1D from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1D from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1D from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1A from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1A from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1A from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Figure 1 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Figure 1 from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Figure 1 from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1B from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1B from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1B from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1C from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1C from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1C from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Supplementary Table 1C from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Supplementary Table 1C from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Supplementary Table 1C from ZIC1 Overexpression Is Oncogenic in Liposarcoma
View article: Data from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Data from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Liposarcomas are aggressive mesenchymal cancers with poor outcomes that exhibit remarkable histologic diversity (there are five recognized subtypes). Currently, the mainstay of therapy for liposarcoma is surgical excision because liposarco…
View article: Data from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma
Data from <i>ZIC1</i> Overexpression Is Oncogenic in Liposarcoma Open
Liposarcomas are aggressive mesenchymal cancers with poor outcomes that exhibit remarkable histologic diversity (there are five recognized subtypes). Currently, the mainstay of therapy for liposarcoma is surgical excision because liposarco…
View article: A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma Open
Purpose: Dedifferentiated liposarcoma (DDLS), one of the most common and aggressive sarcomas, infrequently responds to chemotherapy. DDLS survival and growth depend on underexpression of C/EBPα, a tumor suppressor and transcriptional regul…